EMA looks into making timing of PIP submissions better for pharma
This article was originally published in SRA
Executive Summary
The European Medicines Agency is working on how to solve a problem that a number of companies complain about when complying with the EU Paediatric Regulation - namely that they have to submit pediatric investigation plans (PIPs) too early in the product development cycle.